Trial Profile
Phase II Study of Olaparib in Subjects With Malignant Mesothelioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 22 Feb 2021 Status changed from recruiting to completed.
- 15 Jul 2020 Planned End Date changed from 1 Dec 2020 to 31 Dec 2020.
- 15 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 31 Dec 2020.